Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Erratum to: Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

BioDrugs. 2016 Oct;30(5):483. No abstract available.

PMID:
27699710
2.

Chemical JAK inhibitors for the treatment of rheumatoid arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

Expert Opin Pharmacother. 2016 Oct 3. [Epub ahead of print]

PMID:
27690665
3.

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.

Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, Saito K, Tanaka Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):834-841.

PMID:
27607196
4.

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

BioDrugs. 2016 Oct;30(5):407-419. Review. Erratum in: BioDrugs. 2016 Oct;30(5):483.

PMID:
27577235
5.

Baricitinib for the treatment of rheumatoid arthritis.

Kubo S, Nakayamada S, Tanaka Y.

Expert Rev Clin Immunol. 2016 Sep;12(9):911-9. doi: 10.1080/1744666X.2016.1214576.

PMID:
27427830
6.

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report.

Kurozumi A, Okada Y, Arao T, Miyazaki Y, Yoshikawa M, Torimoto K, Kubo S, Nakayamada S, Tanaka Y.

Endocrinol Diabetes Metab Case Rep. 2016;2016:160020. doi: 10.1530/EDM-16-0020.

7.

T follicular helper (Tfh) cells in autoimmune diseases.

Nakayamada S, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(1):1-7. doi: 10.2177/jsci.39.1.

8.

Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold.

Sonomoto K, Yamaoka K, Kaneko H, Yamagata K, Sakata K, Zhang X, Kondo M, Zenke Y, Sabanai K, Nakayamada S, Sakai A, Tanaka Y.

PLoS One. 2016 Apr 7;11(4):e0153231. doi: 10.1371/journal.pone.0153231.

9.

A twin study of rheumatoid arthritis in the Japanese population.

Terao C, Ikari K, Nakayamada S, Takahashi Y, Yamada R, Ohmura K, Hashimoto M, Furu M, Ito H, Fujii T, Yoshida S, Saito K, Taniguchi A, Momohara S, Yamanaka H, Mimori T, Matsuda F.

Mod Rheumatol. 2016 Sep;26(5):685-9. doi: 10.3109/14397595.2015.1135856.

PMID:
26727555
10.

Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome.

Zhao J, Kubo S, Nakayamada S, Shimajiri S, Zhang X, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2016 Sep;26(5):716-24. doi: 10.3109/14397595.2015.1129694.

PMID:
26706891
11.

[Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].

Nakayamada S, Tanaka Y.

Clin Calcium. 2015 Dec;25(12):1787-93. doi: CliCa151217871793. Japanese.

PMID:
26608853
12.

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.

Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y.

Ann Rheum Dis. 2016 Jul;75(7):1321-7. doi: 10.1136/annrheumdis-2015-207784.

PMID:
26245754
13.

Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia.

Ogasawara A, Kakeda S, Watanabe K, Ide S, Ueda I, Murakami Y, Moriya J, Futatsuya K, Sato T, Nakayamada S, Saito K, Tanaka Y, Liu T, Wang Y, Korogi Y.

Eur Radiol. 2016 Apr;26(4):1056-63. doi: 10.1007/s00330-015-3929-3.

PMID:
26228900
14.

Histamine inhibits differentiation of skin fibroblasts into myofibroblasts.

Lin L, Yamagata K, Nakayamada S, Sawamukai N, Yamaoka K, Sakata K, Nakano K, Tanaka Y.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):434-9. doi: 10.1016/j.bbrc.2015.05.094.

PMID:
26036574
15.

Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap.

Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Horita T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Ohmura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F.

Arthritis Rheumatol. 2015 May;67(8):2226-32. doi: 10.1002/art.39157.

16.

[Abnormal expression of chemokine receptor on B cells in patients with SLE].

Yoshikawa M, Nakayamada S, Iwata S, Kubo S, Yunoue N, Wang SP, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(1):65-8. doi: 10.2177/jsci.38.65. Japanese.

17.

Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation.

Wang SP, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, Kubo S, Yoshikawa M, Tanaka Y.

Rheumatology (Oxford). 2015 Aug;54(8):1488-97. doi: 10.1093/rheumatology/keu532.

18.

Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.

Nakayamada S, Iwata S, Tanaka Y.

Int J Rheum Dis. 2015 Feb;18(2):208-18. doi: 10.1111/1756-185X.12534. Review.

PMID:
25557245
19.

Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.

Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang SP, Yoshikawa M, Saito K, Tanaka Y.

Arthritis Rheumatol. 2015 Jan;67(1):63-73. doi: 10.1002/art.38895.

20.

Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.

Wang SP, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y.

Ann Rheum Dis. 2014 Dec;73(12):2213-5. doi: 10.1136/annrheumdis-2014-205615. No abstract available.

PMID:
25157177
Items per page

Supplemental Content

Loading ...
Support Center